Trial Profile
A Multicenter Prospective Smile Study investigate factors associated with the extent of symptoms and QOL improvement for First-Line Egfr-Tkis in Nsclc.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2017
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer